20 results about "Treatment research" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

The invention discloses application of a caenorhabditis elegans reproductive disorder model to screening of strains promoting reproduction health, and relates to the technical field of biologica.Cyclophosphamide medicine intervention is applied to caenorhabditis elegans, so that the normal reproductive system of caenorhabditis elegans is damaged, and the reproductive disorder model is prepared; then 3985 gene knockout strains in an escherichia coli Keio gene knockout library are utilized, and strains with the reproductive capacity remarkably improved for reproductive disorder are screened; and carrying out homologous gene knockout on the probiotics by using a gene editing technology, and screening out the probiotics with the potential of promoting reproductive health. The reproductive disorder model is stable and repeatable, can be used for screening strains or drugs for improving the reproductive function, and also can be used for screening candidate strains or drugs for reducing the reproductive toxicity of cyclophosphamide. According to the method, an effective tool is provided for screening of reproduction-related probiotic strains or screening of related drugs, and meanwhile, the strains screened based on the model provide new candidate strains for treatment and research of reproductive disorder diseases.

The invention belongs to the technical field of medical experimental animal models, provides a construction method of a dry age-related macular degeneration animal model, and aims to break through the technical bottlenecks of long construction period, high cost and incomplete pathological feature coverage of an existing model. D-galactose is used for inducing glycosylation end product accumulation and mitochondrial dysfunction, oxidative stress, RPE metabolic disorder and inflammation microenvironment in the dry AMD pathogenesis process can be synchronously simulated, core pathological characteristics such as retina glass membrane wart deposition, RPE atrophy, retina and visual function damage and the like can be accurately reproduced, meanwhile, a multi-dimensional verification system is matched, and the method has the advantages that the method is simple and convenient to operate and high in practicability. The method is suitable for preclinical evaluation of personalized treatment strategies; besides, the method is short in modeling period, the animal model meeting the requirement can be obtained within 8 weeks, the cost advantage is outstanding, and an efficient and reliable experimental animal model can be provided for dry AMD treatment research.

The invention belongs to the technical field of biological medicines, and particularly relates to sulfonium salt polypeptide or protein as well as a preparation method and application thereof. Polypeptide or protein containing cysteine and a sulfonium salt compound are used as raw materials, and the sulfonium salt compound is used for alkylation of cysteine at a specific site of the polypeptide or protein to prepare the sulfonium salt polypeptide or protein. The sulfonium salt polypeptide or protein is used as a probe for covalently labeling tryptophan in a lysine methylation reader protein recognition pocket. According to the method disclosed by the invention, different types of sulfonium salt polypeptides and protein probes can be simply, conveniently and efficiently prepared, and the designed annular sulfonium salt with a novel skeleton has an obvious improvement on the polypeptide or protein labeling yield of reader protein. The prepared sulfonium salt probe not only can be used for identifying lysine methylation modified reader protein and finding a therapeutic target for disease-related pathways, but also can be used for modifying tryptophan at a specific site of an antibody-coupled drug and provides a powerful tool for targeted therapy research of tumors.

This application relates to the technical field of medical research and clinical experiments, and provides an experimental method for clinical research of targeting molecules based on an atrial fibrillation warning system. The method includes: continuously monitoring dynamic electrocardiograms of a patient using an atrial fibrillation warning system; when the atrial fibrillation warning system issues an alert indicating imminent atrial fibrillation, immediately collecting blood or other clinical information of the patient; collecting blood or other clinical information of the patient when the patient has not experienced atrial fibrillation and the atrial fibrillation warning system has not issued an alert, to serve as control data; comparing biological indicators during atrial fibrillation occurrence and non-occurrence, and analyzing potential triggering factors and targeting molecules; and based on the identified targeting molecules, conducting targeted treatment research to validate effectiveness of the targeting molecules.

The invention discloses an AML chemotherapy regimen sharing method and system based on distributed processing, and belongs to the technical field of medical information. The method comprises the following steps: acquiring clinical data related to an AML chemotherapy regimen, including patient information, pathological indexes and iconography data, performing preprocessing and semantic annotation, and generating a semantic clinical data unit with a distributed identifier; registering the identifier, the metadata and the digital signature to a distributed account book network maintained by multiple mechanisms; receiving a query request based on the semantic tag and the metadata, and matching a data unit in an account book network through a semantic engine; and after verifying the authority of the requester, transmitting a data load or executing a distributed computing task of which the data cannot be out of the domain through the secure channel. The problems of privacy security, cross-mechanism interoperation and credible authentication in clinical data sharing are effectively solved, and an efficient and reliable data collaboration platform is provided for AML diagnosis and treatment research.

The invention belongs to the technical field of tumor molecular biology, and discloses a digestive tract tumor cross-cancer-species molecular typing method and application thereof. According to the method, six-dimensional molecular characteristics are integrated by using a robust rank polymerization algorithm, and high-confidence functional genes are screened through RNAi and CRISPR dual verification, so that the problems of single dimension and insufficient specificity of traditional screening are solved, the functional gene screening is more accurate, and a reliable foundation is laid for typing; the method has the advantages that tissue origin limitation is broken through, unified typing of the generic gastrointestinal tumors is realized, stability is verified in multi-queue and multi-technical platform samples by determining four types of subtypes, stability and unification of cross-cancer type typing are realized, and a new standardized diagnosis and treatment thought is provided. The molecular subtype determined by the method is used for in-vitro drug response prediction for non-diagnosis / treatment purposes, a scientific basis is provided for risk stratification and individualized medication research, precise treatment research is further promoted, and clinical guidance value is outstanding.

The invention discloses a novel anti-tumor two-dimensional photothermal material and a preparation method thereof.The preparation method comprises the steps that after a BP nanosheet is prepared through a liquid stripping technology, Fe < 3 + > is introduced, FeBPs is prepared through an in-situ biomimetic mineralization method, BP is subjected to in-situ biomimetic mineralization through metal ions Fe < 3 + >, and the black phosphorus nanosheet-(FeBPs) with the surface modified by an iron-phosphoric acid organic coordination layer is constructed. After the FeBPs enter tumor cells, dissociation of a mineralization layer is initiated under the synergistic effect of GSH, Fe < 3 + > is reduced into Fe < 2 + >, a large amount of GSH in the cells is consumed, the GPX4 protein level is lowered, ROS accumulation is caused, and tumor cell ferroptosis is induced. Meanwhile, by means of the excellent photo-thermal performance of BP after dissociation of the mineralization layer, under irradiation of near-infrared light 808 nm, the temperature of tumor tissue is increased, tumor ablation is caused, then photo-thermal / ferroptosis collaborative treatment is achieved, and a new treatment strategy is provided for tumor treatment research.

This invention provides a dual-target nucleic acid aptamer, conjugate, preparation method, and application. Using Nectin4 and c-Met as dual targets, this invention designs and constructs a dual-target nucleic acid aptamer-MMAE conjugate. Stable conjugation between the nucleic acid aptamer and MMAE is achieved through a maleimide-thiol specific reaction. Through systematic structural characterization, in vitro functional verification, and in vivo imaging and therapeutic studies, the invention verifies the conjugate's targeting ability for bladder cancer, in vitro antitumor activity, and in vivo tumor enrichment and growth inhibition effects. This addresses the problem of insufficient MMAE targeting, providing a new experimental model and theoretical basis for nucleic acid aptamer-mediated targeted delivery of small molecule cytotoxic drugs, and exploring new strategies for dual-target precision treatment of bladder cancer.

This application relates to the fields of biomedical engineering and neuromodulation, disclosing the application of ultrashortwave in the fabrication of devices for modulating brain neural activity. The modulation of brain neural activity is achieved through the non-thermal effects of ultrashortwave, which refers to ultrashortwave with a frequency of 27.12MHz ± 0.6%, a wavelength of 11.06 nm, and a power of 1.6 ± 0.72 W. This application breaks through the traditional technical prejudice that high-frequency electric fields are unsuitable for the central nervous system, proving that non-thermal ultrashortwave can be safely used for brain neural modulation, opening up a completely new technical direction for neural modulation. With "ultrashortwave + application scenario" as its core protection element, it provides fundamental patent support for research on the treatment of various central nervous system diseases such as Parkinson's disease, stroke, depression, and Alzheimer's disease, possessing extremely high core patent value and broad clinical translation prospects.

The present application relates to the field of medicine, and particularly relates to a liposome loaded with phagolysosomal peptide, a preparation method and application thereof, so as to provide a drug for treating pancreatitis, and meanwhile improve the bioavailability of the drug. The liposome loaded with phagolysosomal peptide comprises phagolysosomal peptide and a shell coated on the periphery of the phagolysosomal peptide, the shell comprises an inner layer and an outer layer, the shell component is distearoyl phosphatidyl ethanolamine-polyethylene glycol, and there is a selenium-selenium bond between the inner layer and the outer layer. The inventor of the present application first discloses the direct effect and mechanism of the phagolysosomal peptide on the damaged pancreas of SAP, and the prepared DSSM@TN liposome can inhibit P2X7-induced mitochondrial damage, accumulation of ROS and expression of NLRP3, improve the bioavailability of the phagolysosomal peptide, significantly enhance the efficacy of the phagolysosomal peptide, and further improve the potential of the phagolysosomal peptide in preventing and treating SAP in the clinic. The DSSM@TN liposome can be used as a drug for treating pancreatitis, and meanwhile provides a new direction for the treatment research of pancreatitis.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of NUPR1 in extracellular inhibition of protein translation. Specifically, experiments prove that NUPR1 can be directly combined with ribosome outside cells to compete for mRNA binding sites and induce the conformational change of the ribosome, so that powerful inhibition on in-vitro protein translation is realized; and meanwhile, based on the conservative property of a ribosome mRNA channel, the effect is speculated to be suitable for other eukaryotic cell lines. The findings not only reveal the specific action mechanism of the NUPR1 in protein translation regulation, but also provide key theoretical basis and experimental basis for subsequent development of short-peptide protein translation inhibitors (such as short peptides simulating NUPR1 binding structural domains) based on the NUPR1, and have important significance on targeted therapy research of related diseases.

The invention discloses a carya illinoensis black spot pathogenic bacterium and application thereof.The carya illinoensis black spot pathogenic bacterium can infect carya illinoensis to generate the black spot, has high pathogenicity, can be used for research on the carya illinoensis black spot, and is beneficial to research on prevention and treatment of the carya illinoensis black spot; the method can be used for screening and developing the carya illinoensis black spot disease prevention and treatment agent.

The invention belongs to the technical field of biological medicine and gene therapy, and particularly relates to a tRNA binding protein assisted termination codon readthrough system and application thereof. The tRNA binding protein assisted termination codon reading-through system disclosed by the invention comprises inhibitory tRNA and binding protein thereof, wherein the inhibitory tRNA contains 70 pairs of G3: U, can be recognized by an endogenous alanyl-tRNA synthetase (AlaRS) of a cell, and is loaded with alanine; the tRNA binding protein is specifically bound with any structure, except for a receptor arm, of the corresponding tRNA, and can be specifically bound with a tRNA binding structural domain of pyrrole lysyl-tRNA synthetase. According to the system, alanine can be introduced in the translation process of a target gene carrying nonsense mutation, so that full-length translation of protein is recovered. The system can be applied to functional recovery and treatment research of various genetic diseases caused by the early termination codon.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an IL-17A inhibitor in preparation of a medicine for treating Alzheimer's disease, and the IL-17A inhibitor is an anti-IL-17A neutralizing antibody and / or an intestinal flora scavenger. The IL-17A inhibitor is used for inhibiting an IL-17A signal and blocking or relieving periodontosis related to NLRP3 inflammasome, so that periodontosis coverage and homeostasis are maintained or recovered, the brain microvascular structure is improved, blood-brain barrier leakage is reduced, the cognitive function is improved, and the compound can be used for prevention and treatment research and drug development of Alzheimer's disease and related cognitive impairment.

The invention discloses a construction method of a shRNA knock-down plasmid for inhibiting expression of a human CASP7 gene and application of the shRNA knock-down plasmid in treatment of non-small cell lung cancer. The target sequence of the shRNA knock-down plasmid for inhibiting the expression of the human CASP7 gene is shRNA3 (short hairpin ribonucleic acid 3). The method comprises the following steps: firstly, designing a DNA sequence containing shRNA (short hairpin Ribonucleic Acid) for inhibiting human CASP7 gene expression; the DNA sequence is cloned to a lentiviral vector pLKO.1 to obtain pLKO.1-CASP7-shRNA recombinant plasmid, then lentiviral packaging is performed, human non-small cell lung cancer cells are infected, the nucleic acid and protein level of CASP7 can be greatly reduced, the pyroptosis level of the non-small cell lung cancer cells can be remarkably improved, and the proliferation capacity of cancer cells can be remarkably inhibited. The shRNA knock-down plasmid disclosed by the invention can be applied to the function research of CASP7, and has an extremely important value for the treatment research of diseases caused by CASP7.

The invention discloses application of a D264N mutant related gene / protein thereof in HIV virus infection diseases, and belongs to the technical field of HIV treatment research. According to the application, human KLF7 and D264N mutant gene recombinant protein thereof are constructed and applied to drugs for inhibiting HIV virus infection. The invention finds that the wild type and the D264N mutant have a remarkable reduction effect on the HIV virus titer. Compared with a control group without overexpression of the KLF7 protein, the virus titers of an experimental group with overexpression of the wild type and the D264N mutant are both reduced by 85% or above, which indicates that the two proteins both have an inhibition effect on HIV virus replication.

The application relates to the field of intelligent medical treatment, in particular to a method, system and device for computer-aided screening of drugs based on UQCC2 and METTL3. It is found for the first time that UQCC2 is significantly highly expressed in osimertinib-resistant lung cancer, and the interaction between UQCC2 and METTL3 is found, which provides an efficient and rapid method for diagnosing osimertinib-resistant lung cancer patients, predicting the drug treatment effect of osimertinib-resistant lung cancer patients and screening drugs based on targeting UQCC2 and METTL3, and has important research significance for disease prevention and treatment research.

The invention discloses an antibody for specifically recognizing ATAD3A phosphorylation modification and application of the antibody. According to the present invention, the research results show that the ATAD3A Ser321 site in senescent cells is the key phosphorylation site, and the antibody specifically recognizing ATAD3A Ser321 phosphorylation is obtained through immunization aiming at the site; the antibody has relatively strong specificity, and can be used for successfully detecting the expression of phosphorylated ATAD3A in senescent cells and the level of phosphorylated ATAD3A in tissues and organs of mice. According to the antibody, the market vacancy that a specific detection antibody for ATAD3A phosphorylation is lacked at present is filled, the antibody can be applied to Western blot and immunohistochemical detection of ATAD3A phosphorylation level in scientific research, and support is provided for mitochondrial related action mechanisms and anti-aging treatment research in the aging process.